摘要
目的探讨循证护理在奥沙利铂联合全直肠系膜切除手术治疗直肠癌护理中的意义及效果分析。方法选取我院收治的72例采用奥沙利铂联合全直肠系膜切除手术治疗的直肠癌患者,随机分为对照组和观察组,对照组采用常规护理,观察组采用循证护理。比较两组患者的不良反应发生情况、治疗后疼痛程度、QOL评分、自我护理能力以及临床疗效。结果观察组治疗后不良反应发生率显著低于对照组(P<0.05),疼痛程度显著低于对照组(P<0.05),QOL评分显著高于对照组(P<0.05),自我护理能力显著优于对照组(P<0.05),护理满意度显著高于对照组(44.4%vs. 72.2%,P<0.05),总缓解率显著高于对照组(30.5%vs. 55.6%,P<0.05)。结论循证护理可明显减轻直肠癌患者的术后不良反应,缓解疼痛,提高临床疗效,改善生活质量和护理满意度,值得临床推广应用。
Objective To explore the significance and effect of evidence-based nursing on rectal cancer patients treated by oxaliplatin combined with total mesorectal excision. Methods Seventy-two patients with rectal cancer treated by oxaliplatin combined with total mesorectal excision were randomly divided into the control group and the observation group. The control group received routine nursing and the observation group got evidence-based nursing. The incidence of adverse reactions, the degree of pain after treatment, QOL score, self-care ability and clinical efficacy were compared between the two groups. Results The incidence of adverse reactions was lower in the observation group than in the control group (P<0.05). The pain level of the observation group was lower than that of the control group (P<0.05). The QOL score of the observation group was higher than that of the control group (P<0.05). In addition, the self-care ability of the observation group was better than that of the control group (P<0.05). The total satisfaction rate of the observation group was also significantly higher than that of the control group (44.4% vs.72.2%, P<0.05). After treatment, the total response rate of the observation group was significantly higher than that of the control group (30.5% vs.55.6%, P<0.05). Conclusion Evidence-based nursing could significantly reduce the adverse reaction rate, complications and pain of patients after rectal cancer surgery. It could also improve the clinical efficacy of treatment, the quality of life and satisfaction of patients. So it is worthy of wide clinical application.
作者
靳丽伟
张岩
马洪
宋先敏
陈桂芸
JIN Liwei;ZHANG Yan;MA Hong;SONG Xianmin;CHEN Guiyun(The Third Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,150040,China)
出处
《肿瘤药学》
CAS
2018年第6期996-1000,共5页
Anti-Tumor Pharmacy
基金
国家自然科学基金资助项目(81772827)